Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
A live, multi-source view of Rhythm Pharmaceuticals, Inc. (RYTM): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 414 employees · rhythmtx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Rhythm Pharmaceuticals, Inc. (RYTM) had a market capitalization of $7.07B (forward -167.3) and a beta of 1.97; the shares traded in a 52-week range of $74.50 – $122.20 (5.1% over the year).
- Market cap
- $7.07B
- Enterprise value
- $6.97B
- Forward P/E
- -167.3
- Price / book
- 68.68
- EPS (trailing)
- $-3.05
- EPS (forward)
- $-0.61
- Payout ratio
- 0.0%
- 52-week range
- $74.50 – $122.20
- 52-week change
- 5.1%
- Beta
- 1.97
- Average volume
- 763,909
- Shares outstanding
- 68.9M
- Short % of float
- 14.86%
- Profit margin
- -85.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Rhythm Pharmaceuticals, Inc. (RYTM) last closed at $102.20 (the last completed close before that scan).
Technicals at the scan: RSI 38 (neutral territory), price -6.3% versus its 20-day average, 20-day versus 50-day average spread +0.1%, MACD histogram -1.22.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 79/100.
Next scheduled company event: in 53 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RYTM; corporate insiders filed 0 buys and 15 sells (5 distinct filers, latest disclosure 2026-09-01). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Yann Mazabraud (0B/6S), Alastair Garfield (0B/4S), Hunter C. Smith (0B/3S), Joseph Shulman (0B/1S), Jennifer Kayden Lee (0B/1S). Who is trading what
RapidTradeView pick record
RYTM has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Rhythm Pharmaceuticals, Inc. (RYTM) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RYTM.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.